CD274 and glioblastoma: Based on the multiplexed immunofluorescence studies that are presented here, it appears that CMV‐specific ACT is effective in significantly prolonging survival in patients with recurrent GBM when there are a few PD‐L1+ cells in the tumor tissue prior to therapy.